Publications

STORM publications

Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies

Kyriakos P. Papadopoulos1, Justin C Moser2, Jordi Rodon3, Yaara Ofir-Rosenfeld4, Hendrik Weisser4, Melinda Snyder4, Tess Schmalbach4, Tess Barker4, Deepa Deshpande4, Ben Skead4, Doug Hester2, Nidhi Sheth2, Pamela Saldana Leon3, Edwin Blanco-Cepeda1, Oliver Rausch4, Josefin-Beate Holz4

1 START San Antonio, San Antonio, TX, US
2 HonorHealth Research Institute, Scottsdale, AZ, US
3 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, US
4 Storm Therapeutics Ltd, Cambridge, Cambridgeshire, UK

First results of a Phase 1 study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies, October 2024, EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics 2024

Jordi Rodon Ahnert1, Justin C Moser2, Kyriakos P. Papadopoulos3, Yaara Ofir-Rosenfeld4, Hendrik Weisser4, Melinda Snyder4, Tess Schmalbach4, Tess Barker4, Deepa Deshpande4, Ben Skead4, Doug Hester2, Nidhi Sheth2, Pamela Saldana Leon1, Edwin Blanco-Cepeda3, Oliver Rausch4, Josefin-Beate Holz4

1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX
2 HonorHealth Research Institute, Scottsdale, AZ
3 START San Antonio, San Antonio, TX
4 Storm Therapeutics Ltd, Cambridge, United Kingdom

Download poster

Working towards pandemic preparedness: Inhibiting viral 5' RNA cap methylation with potent, selective, broad-spectrum anti-viral small molecules, October 2024, ELRIG Drug Discovery 2024

Harrison H1, Glen A1, Andrews B1, Bayle E1, Duncan C1, Fyfe M1, Guest P1, Rausch O1, Swain C1, Thomas B1, Zemla-Brown A1, Baric R2, Chen Y2, Froggatt H2, Heise M2, Moorman N2, Morales N2, Scobey T2, Sheahan T2, Taft-Benz S2, Williams A2, McElwee M3, O'Connor L3, Patel AH3, Szemiel AM3

1 STORM Therapeutics Limited, Babraham Research Campus, Cambridge, United Kingdom
2 AViDD-READDI, University of North Carolina, Chapel Hill, North Carolina, USA
3 CVR-CRUSH Drug-Screening and Resistance Hub, MRC-University of Glasgow Centre for Virus Research (CVR), Glasgow, United Kingdom

Download poster

Inhibiting coronavirus 5' RNA capping with potent, selective, FIC small molecules, May 2024, 4th SCI / RSC Symposium on Anti-Infectives Drug Discovery

Angela Glen1 , Byron Andrews1 , Ralph Baric2a, Elliot Bayle1 , Caitlin Duncan1 , Matthew Fyfe1 , Patrick Guest1 , Helen Harrison1 , Mark Heise2b, Nat Moorman2c, Oliver Rausch1 , Trevor Scobey2a, Tim Sheahan2a, Chris Swain1 , Sharon Taft-Benz2b, Beth Thomas1 , Aleksandra Zemla-Brown1

1STORM Therapeutics Ltd, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom

2AViDD-READDI, Rapidly Emerging Antiviral Drug Development Initiative (READDI): a) Department of Epidemiology, UNC Chapel Hill, Gillings School of Public Health; b) Department of Genetics, UNC Chapel Hill, School of Medicine; c) Department of Microbiology and Immunology, UNC Chapel Hill, School of Medicine

Download poster

STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses and synergizes with immune checkpoint blockade, Nov 2022, SITC Annual Meeting 2022

Joanna Obacz1, Yaara Ofir-Rosenfeld1, Lina Vasiliauskaitė1, Claire Saunders1*, Alexandra Sapetschnig1, Georgia Tsagkogeorga1,2, Mark Albertella1+, Marie Carkill3, Jezrom Self-Fordham3, Josefin-Beate Holz1, Oliver Rausch1 and Jerry McMahon1

1Storm Therapeutics Ltd, Cambridge, UK | 2Milner Therapeutics Institute, University of Cambridge, Cambridge, UK | 3Charles River, Portishead, UK *Current address: UCL Cancer Institute, London, UK | +Current address: Oncology R&D, AstraZeneca, Cambridge UK

STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade, Oct 20

Yaara Ofir-Rosenfeld1, Lina Vasiliauskaitė1, Claire Saunders1*, Alexandra Sapetschnig1, Georgia Tsagkogeorga1,2, Mark Albertella1+, Marie Carkill3, Jezrom Self-Fordham3, Josefin-Beate Holz1, Oliver Rausch1 and Jerry McMahon1

1Storm Therapeutics Ltd, Cambridge, UK | 2Milner Therapeutics Institute, University of Cambridge, Cambridge, UK | 3Charles River, Portishead, UK | *Current address: UCL Cancer Institute, London, UK |+Current address: Oncology R&D, AstraZeneca, Cambridge UK

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia, May 2021, Nature

Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG, Webster NA, Andrews B, Fosbeary R, Guest P, Irigoyen N, Eleftheriou M, Gozdecka M, Dias JML, Bannister AJ, Vick B, Jeremias I, Vassiliou GS, Rausch O, Tzelepis K, Kouzarides T.

593(7860):597-601. doi: 10.1038/s41586-021-03536-w. Epub 2021 Apr 26.PMID: 33902106

Other relevant publications

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade, Jan 2019, Nature

Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN.

565(7737):43-48. doi: 10.1038/s41586-018-0768-9. Epub 2018 Dec 17.PMID: 30559380